Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT03168438
Title Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors GlaxoSmithKline
Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.